Latest Conference Articles

December 4th 2016, 9:27am

ASH Annual Meeting and Exposition

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

December 4th 2016, 8:37am

ASH Annual Meeting and Exposition

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

December 4th 2016, 6:42am

ASH Annual Meeting and Exposition

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

December 4th 2016, 5:56am

ASH Annual Meeting and Exposition

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

December 4th 2016, 4:30am

ASH Annual Meeting and Exposition

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

December 4th 2016, 3:38am

ASH Annual Meeting and Exposition

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

December 4th 2016, 2:53am

ASH Annual Meeting and Exposition

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

December 3rd 2016, 11:54pm

ASH Annual Meeting and Exposition

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

November 22nd 2016, 4:15am

Society for Neuro-Oncology Annual Meeting

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

November 22nd 2016, 1:57am

Society for Neuro-Oncology Annual Meeting

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

November 20th 2016, 3:23am

Society for Neuro-Oncology Annual Meeting

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

November 20th 2016, 3:08am

Society for Neuro-Oncology Annual Meeting

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

November 20th 2016, 1:39am

Society for Neuro-Oncology Annual Meeting

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

November 20th 2016, 1:25am

Society for Neuro-Oncology Annual Meeting

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.

November 19th 2016, 10:35pm

Society for Neuro-Oncology Annual Meeting

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

November 19th 2016, 9:40pm

Society for Neuro-Oncology Annual Meeting

November 19th 2016, 6:47am

Society for Neuro-Oncology Annual Meeting

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

November 19th 2016, 6:19am

Society for Neuro-Oncology Annual Meeting

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

November 19th 2016, 3:05am

Society for Neuro-Oncology Annual Meeting

November 19th 2016, 2:54am

Society for Neuro-Oncology Annual Meeting